California sits atop an enormous shale deposit, raising the prospect of significant fracking activity. State regulators and lawmakers are looking to adopt new regulations. How much financial muscle is the oil and natural gas industry flexing in the decision being made about fracking in California?
A grieving father set out to create a system that might prevent other lives from being lost at the hands of a drug-dazed driver. Ten years later, he's still waiting for the system he created to be fully realized.
Despite being for-profit institutions, Sierra Vista and Twin Cities Community Hospital lead the way in providing care to those less fortunate in the region.
LaVonna Blair Lewis, Ph.D., MPH, is a Teaching Associate Professor at the USC School of Policy, Planning, and Development. Dr. Lewis joined the USC faculty in 1996 and she was selected Professor of the Year at the school in 1998 and 2001. She has a Ph.D. in political science from Rice University.
For the past year and a half, Julie Sullivan at the Oregonian, one of the country’s most consistent and skilled investigative reporters, has been writing about troops that were exposed to the cancer-causing chemical hexavalent chromium in Iraq.
ReportingonHealth’s Antidote blogger, William Heisel, recently posted his 10 favorite stories of the year. Most of them had an investigative bent. Now, it’s my turn.
Follow the money. That simple phrase – though never uttered by Bob Woodward’s most famous source – has propelled countless reporters to dig deeply into all manner of news stories.
And nearly four decades after Woodward and Carl B
Dr. Adriane Fugh-Berman has become the go-to source for comments on how drug companies have been using ghostwriters to inject marketing messages into the medical literature, a controversy that prompted powerful Sen. Charles Grassley, R-Iowa, to send a letter on Aug. 11 to the National Institutes of Health asking, among other things, "What is the current NIH policy on ghostwriting with regards to NIH researchers?"
The decision by Astra Zeneca to stop the so-called JUPITER trial of its Crestor cholesterol medication last year garnered a ton of press attention. The New York Times captured the general tone of the coverage with this lead on a front-page story.
Update: Dr. Gupta removed himself from the list of candidates on March 5, telling CNN's Larry King, "I think for me it really came down to a sense of timing more than anything else. This job...takes us away from our children for so many years at once, and I sort of came to grips that I'd probably be away for several years of their lives."
Dr. Sanjay Gupta appears to be the first surgeon general picked not for his public service but for his public image.
